Schell Michael J, Yankaskas Bonnie C, Ballard-Barbash Rachel, Qaqish Bahjat F, Barlow William E, Rosenberg Robert D, Smith-Bindman Rebecca
Biostatistics Division, Department of Interdisciplinary Oncology, Moffitt Research Center, 12902 Magnolia Dr, Tampa, FL 33612-9497, USA.
Radiology. 2007 Jun;243(3):681-9. doi: 10.1148/radiol.2433060372.
To retrospectively identify target recall rates for screening mammography on the basis of how sensitivity shifts with recall rate.
The study group included 1 872 687 subsequent and 171 104 first screening mammograms from 1996 to 2001 from 172 and 139 facilities, respectively, in six sites of the Breast Cancer Surveillance Consortium. Institutional review board (IRB) approval was obtained from each site. Informed consent requirements of the IRBs were followed. The study was HIPAA compliant. Recall rate was defined as the percentage of screening studies for which further work-up was recommended by the radiologist. Sensitivity was defined as the proportion of cancers that were detected at screening mammography. Piecewise linear regression was used to model sensitivity as a function of recall rate. This model allows detection of critical recall rates in which significant changes (shifts) occurred in the rates that sensitivity increased with increasing recall rate. Rates were interpreted as number of additional work-ups per additional cancer detected (AW/ACD) or, in other words, the estimated number of additional women needed to be recalled at a given rate to detect one additional cancer.
For first mammograms, a single shift in the estimated AW/ACD rate occurred at a recall rate of 10.0%, with the rate jumping dramatically from 35 to 172. For subsequent mammograms, four shifts were identified. At a recall rate of 6.7%, the estimated AW/ACD increased from 80 to 132, which rendered it the highest desirable target recall rate. At a recall rate of 12.3%, the estimated AW/ACD was 304, which suggests little benefit for any higher recall rate.
Recall rates of 10.0% for first and 6.7% for subsequent mammograms are recommended targets on the basis of their AW/ACD rates (less than 100).
根据敏感度随召回率的变化情况,回顾性确定乳腺钼靶筛查的目标召回率。
研究组包括1996年至2001年分别来自乳腺癌监测联盟6个地点的172个和139个机构的1872687例后续乳腺钼靶筛查和171104例首次乳腺钼靶筛查。各地点均获得了机构审查委员会(IRB)的批准。遵循了IRB的知情同意要求。该研究符合《健康保险流通与责任法案》(HIPAA)。召回率定义为放射科医生建议进一步检查的筛查研究的百分比。敏感度定义为在乳腺钼靶筛查中检测出的癌症比例。采用分段线性回归将敏感度建模为召回率的函数。该模型能够检测出敏感度随召回率增加而显著变化(偏移)时的关键召回率。召回率被解释为每多检测出一例癌症所需的额外检查次数(AW/ACD),或者换句话说,在给定召回率下为检测出一例额外癌症所需召回的额外女性数量的估计值。
对于首次乳腺钼靶筛查,估计的AW/ACD率在召回率为10.0%时出现一次偏移,该率从35急剧跃升至172。对于后续乳腺钼靶筛查,识别出四次偏移。在召回率为6.7%时,估计的AW/ACD从80增加到132,这使其成为最理想的目标召回率。在召回率为12.3%时,估计的AW/ACD为304,这表明更高的召回率几乎没有益处。
基于其AW/ACD率(小于100),建议首次乳腺钼靶筛查的召回率为10.0%,后续乳腺钼靶筛查的召回率为6.7%。